Xconomy: Indel Therapeutics Aims High With New Class of Antibiotics to Fight Hospital Infections
Summary
Indel Therapeutics Aims High With New Class of Antibiotics to Fight Hospital Infections (Page 2 of 2) between proteins found in the pathogen and in people.The company bought 240 small-molecule drugs from the University of California, San Francisco last fall, and is using them to run experiments that can verify if its targets are any good.One thing about antibiotics is that the animal models tend to be more predictive of success than for cancer drugs, say, which means the company should be able to drum up more interest at a relatively early stage, Kendall says.South San Francisco-based Achaogen recently won a five-year, $26.6 million grant from the National Institutes of Health to discover and develop drugs against this potential bioterrorist agent.Since the government is willing to pay for that kind of research, and the yersinia bug has some genetic things in common with other pathogens, this might be one way Indel can get some momentum for its business strategy, Kendall says.